28 August 2022 in Journal of Hepatology
Antiviral therapy improves the clinical outcomes of patients with chronic hepatitis B (CHB), including those with cirrhosis. In the present study, we validated the Baveno VII definition of recompensation and explored the criteria for stable improvement of liver function tests in entecavir-treated patients with CHB-related decompensated cirrhosis. In this multicentre prospective study, patients with decompensated (ascites) CHB-related cirrhosis were enrolled and treated with entecavir for 120 weeks. Patients were followed up for clinical events, viral and biochemical tests, and ultrasonography every 6 months. The recompensation rate per Baveno VII criteria was calculated. Multivariate regression models were used to identify the predictors of recompensation. Finally, the criteria for stable improvement of liver function tests were explored. Of the 320 recruited patients, 283 completed the 120-week study, with 261/283 (92.2%) achieving HBV DNA levels <20 IU/ml and 171/283 (60.4%) achieving resolution of ascites, encephalopathy, and absence of recurrent variceal bleeding for at least 12 months. We identified model for end-stage liver disease 35 g/L, international normalised ratio <1.50 and total bilirubin <34 μmol/L) as the criteria for stable improvement of liver function tests. Accordingly, 56.2% (159/283) of patients fulfilled the Baveno VII definition of recompensation with a stable improvement of liver function tests defined by the current study. Our study defined the criteria for a stable improvement of liver function tests required by the Baveno VII definition of recompensation in patients with CHB-related decompensated cirrhosis on antiviral therapy. The criteria derived from this multicentre prospective study warrant further validation in patients with cirrhosis of other aetiologies. Decompensation of cirrhosis marks the point at which the liver is no longer able to function normally (and symptoms become apparent). Recently the idea of recompensation was proposed for individuals who may experience an improvement in liver function if the underlying cause of their liver disease is addressed (e.g. antivirals for viral cirrhosis). Herein, we show that over 50% of patients with hepatitis B-related decompensated cirrhosis treated with antivirals could recompensate and we propose laboratory criteria which could be used to define recompensation.
28 November 2024 in Phytotherapy Research
11 July 2026 in Cellular and Molecular Life Sciences
During chronic liver injury, hepatocytes promote liver fibrosis by interacting with hepatic stellate cells (HSCs). However, the key intracellular factors that regulate intercellular communication in hepatocytes remain poorly understood. Although cluster of differentiation 146 (CD146) is predominantly recognized as an endothelial cell marker, our study found that CD146 is substantially upregulated in hepatocytes under fibrotic stress and may play an independent role in transcellular signaling. This study aimed to elucidate the functions and underlying mechanisms of hepatocyte CD146 in liver fibrosis. We evaluated CD146 expression in liver tissues and serum soluble CD146 (sCD146) levels in patients with liver fibrosis and mouse models. Hepatocyte-specific CD146-overexpressing mice (AAV8-CD146) were generated and fed either a normal chow diet (NCD) or a high-fat diet (HFD); hepatocyte-specific CD146 knockout mice (CD146Alb-Cre) were subjected to carbon tetrachloride (CCl₄)-induced fibrosis. Comprehensive molecular, biochemical, and histological analyses were performed to systematically assess the role of CD146 in the initiation and progression of liver fibrosis. A co-culture system of hepatocytes and HSCs was also established to investigate the paracrine regulatory effects of CD146 on HSCs. The levels of sCD146 were positively correlated with the progression and severity of chronic liver disease. A diagnostic model incorporating sCD146 and other serological markers showed improved diagnostic performance for decompensated cirrhosis. Compared with healthy controls, hepatocyte CD146 expression was markedly upregulated in liver tissues from patients with cirrhosis and fibrotic mice. Under HFD conditions, hepatocyte-specific CD146 overexpression exacerbated hepatic inflammation and fibrosis in mice, whereas hepatocyte-specific CD146 deletion significantly attenuated CCl₄-induced liver fibrosis. Transforming growth factor-β1 (TGF-β1) induced CD146 upregulation in hepatocytes and increased the release of sCD146. Released sCD146 bound to integrin αvβ1 on the surface of HSCs, activated the p38 mitogen-activated protein kinase (p38 MAPK) pathway, and promoted HSC activation and type I collagen production. These findings identify hepatocyte-derived CD146/sCD146 as a TGF-β1-inducible mediator of hepatocyte-HSC communication that promotes liver fibrosis through the CD146/sCD146-integrin αvβ1-p38 MAPK signaling axis. They also support serum sCD146 as a potential non-invasive biomarker for advanced chronic liver disease.